Insider Selling: Boston Scientific Co. (NYSE:BSX) Director Sells 3,946 Shares of Stock

Boston Scientific Co. (NYSE:BSX) Director Charles J. Dockendorff sold 3,946 shares of Boston Scientific stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total transaction of $286,874.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Boston Scientific Trading Up 1.9 %

BSX stock opened at $74.10 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14. The company has a fifty day moving average price of $68.79 and a two-hundred day moving average price of $61.81. Boston Scientific Co. has a one year low of $48.35 and a one year high of $74.39. The stock has a market cap of $108.71 billion, a price-to-earnings ratio of 62.27, a price-to-earnings-growth ratio of 2.51 and a beta of 0.77.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on BSX shares. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Boston Scientific from $63.00 to $73.00 and gave the company a “hold” rating in a report on Thursday, April 25th. StockNews.com cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th. Citigroup raised their target price on shares of Boston Scientific from $79.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Finally, Mizuho raised their target price on shares of Boston Scientific from $80.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.09.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors have recently modified their holdings of the business. FMR LLC boosted its position in shares of Boston Scientific by 6.8% in the third quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock valued at $6,648,595,000 after acquiring an additional 8,045,263 shares during the period. Vanguard Group Inc. boosted its position in shares of Boston Scientific by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 125,449,802 shares of the medical equipment provider’s stock valued at $7,252,253,000 after acquiring an additional 1,681,454 shares during the period. Wellington Management Group LLP boosted its position in shares of Boston Scientific by 5.9% in the third quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock valued at $2,221,641,000 after acquiring an additional 2,336,348 shares during the period. Primecap Management Co. CA boosted its position in shares of Boston Scientific by 1.5% in the fourth quarter. Primecap Management Co. CA now owns 37,905,659 shares of the medical equipment provider’s stock valued at $2,191,326,000 after acquiring an additional 550,490 shares during the period. Finally, Morgan Stanley boosted its position in shares of Boston Scientific by 2.3% in the third quarter. Morgan Stanley now owns 21,200,339 shares of the medical equipment provider’s stock valued at $1,119,378,000 after acquiring an additional 481,891 shares during the period. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.